Novartis, Alnylam Pharmaceuticals, Regulus Therapeutics, Sigma-Aldrich, the RNAi Consortium, Agilent Technologies, Arrowhead Research, Bio-Rad | GenomeWeb
This article has been updated from a previous version to clarify Sigma-Aldrich's role in the validation process.
Novartis Buys Additional Shares of Alnylam Stock
Alnylam Pharmaceuticals this week said that its partner Novartis has exercised an option to purchase 213,888 unregistered shares of Alnylam common stock pursuant to the companies’ 2005 drug-development collaboration.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.